Long-Term Follow-Up in Patients With Acute Myocardial Infarction Cohort

NCT ID: NCT05862103

Last Updated: 2025-09-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

15000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-12-21

Study Completion Date

2026-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

AMI Survivors who participated in the project "Construction and key technology research of the whole myocardial protection system for acute myocardial infarction" (project number 2016YFC1301100) and completed the 1-year visit were followed up by telephone at 3 years (within the corresponding follow-up time window) and 5 years after discharge to acquire the patients' medication, health status, and major adverse cardiovascular and cerebrovascular events, including death, heart failure, rehospitalization, re-myocardial infarction, revascularization, stroke, malignant arrhythmia, and bleeding events.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Myocardial Infarction Adverse Event

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

optimized group

the patients received at least one optimized treatment

Treatment Strategies

Intervention Type OTHER

AMI emergency treatment process, pre-reperfusion medication, reperfusion strategy selection, and early cardiac rehabilitation after reperfusion

un-optimized group

the patients didn't receive optimized treatment

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Treatment Strategies

AMI emergency treatment process, pre-reperfusion medication, reperfusion strategy selection, and early cardiac rehabilitation after reperfusion

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* AMI survivors who participated in the project "Construction and key technology research of the whole myocardial protection system for acute myocardial infarction" and completed the 1-year visit.
* Telephone to obtain informed consent from the subjects/family members of the subjects.

Exclusion Criteria

* Not available
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Yu Bo

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Yu Bo

Director

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bo Yu

Role: STUDY_CHAIR

The Second Affiliated Hospital of Harbin Medical University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Beijing An Zhen Hospital, Capital Medical University

Beijing, Beijing Municipality, China

Site Status RECRUITING

Beijing Chao-Yang Hospital, Capital Medical University

Beijing, Beijing Municipality, China

Site Status RECRUITING

Peking University First Hospital

Beijing, Beijing Municipality, China

Site Status NOT_YET_RECRUITING

Guangdong general hospital

Guangzhou, Guangdong, China

Site Status RECRUITING

The first affiliated hospital of Guangxi medical university

Nanning, Guangxi, China

Site Status RECRUITING

Second hospital of hebei medical university

Shijiazhuang, Hebei, China

Site Status RECRUITING

Daqing Oil Field Hospital

Daqing, Heilongjiang, China

Site Status RECRUITING

The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, China

Site Status RECRUITING

Zhongda Hospital Southeast University

Nanjing, Jiangsu, China

Site Status RECRUITING

The Second Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, China

Site Status RECRUITING

The Second Hospital of Jilin University

Changchun, Jilin, China

Site Status RECRUITING

The econd Affiliated Hospital of Dalian Medical University

Dalian, Liaoning, China

Site Status RECRUITING

General Hospital of Northern Theater Command of the Chinese People's Liberation Army

Shenyang, Liaoning, China

Site Status RECRUITING

Xijing Hospital of Air Force Military Medical University

Xi’an, Shanxi, China

Site Status RECRUITING

Xinqiao Hospital Army Medical University

Chongqing, Sichuan, China

Site Status RECRUITING

The General Hospital of Tianjin Medical University

Tianjin, Tianjin Municipality, China

Site Status RECRUITING

Tianjin Chest Hospital

Tianjin, Tianjin Municipality, China

Site Status RECRUITING

First Affiliated Hospital of Xinjiang Medical University

Ürümqi, Xinjiang, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Xiling Zhang, MD

Role: CONTACT

+86 13804608748

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

ChunMei Wang

Role: primary

13521901670

Lefeng Wang

Role: primary

Jianping Li

Role: primary

Ning Tan

Role: primary

Lang Li

Role: primary

Xinshun Gu

Role: primary

+8613930139688

Zhiqi Sun

Role: primary

+8613304863433

Zhe Meng

Role: primary

+8618137793359

Genshan Ma

Role: primary

Yanqing Wu

Role: primary

Bin Liu, MD, PhD

Role: primary

Peng Qu

Role: primary

Bin Wang

Role: primary

+8615309882359

Zhijing Zhao

Role: primary

+8613772020951

Zhexue Qin

Role: primary

+8615823810730

Wenjuan Zhang

Role: primary

+8613002226922

Chunjie Li

Role: primary

Xiang Ma

Role: primary

+8613669939349

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

KY2022-266

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.